Status:
UNKNOWN
Gallium-68 Labeled Pentixafor PET/CT in Adrenal Masses
Lead Sponsor:
Peking Union Medical College Hospital
Conditions:
Adrenal Mass
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
PHASE3
Brief Summary
The CXC chemokine receptor type 4 (CXCR4), which is a G protein-coupled receptor expressed on the surface of the cell membrane, contributes to the development and progression of malignancies and funct...
Detailed Description
Identifying the functional distinctions between adrenal nodules remains challenging. It is imperative to employ the least invasive approach for the functional evaluation of adrenal masses (e.g., adren...
Eligibility Criteria
Inclusion
- Written informed consent.
- Patients with adrenal diseases.
- A diagnostic computed tomography (CT) or magnetic resonance imaging (MRI) of the adrenal region within the previous 6 months prior to dosing day is available
Exclusion
- Pregnant or breast-feeding women.
- Prior or planned administration of a radiopharmaceutical within 8 half-lives of the radionuclide used on such radiopharmaceutical including at any time during the current study.
- Any mental condition rendering the patient unable to understand the nature, scope and possible consequences of the study, and/or evidence of an uncooperative attitude
Key Trial Info
Start Date :
July 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2022
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT04859959
Start Date
July 1 2018
End Date
December 1 2022
Last Update
April 26 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking Union Medical College Hospital
Beijing, China, 100730